All In Biotech

Drug Trial Radar · NCT06924970

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

59

Actual

Start

May 1, 2025

Primary completion

May 12, 2026

Study completion May 2027

Sponsor

Lead sponsor
Agios Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.

Conditions

  • Sickle Cell Disease

Interventions

  • TebapivatDrug

    Oral tablets.

  • Tebapivat Matched PlaceboDrug

    Oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Hb ResponseTime frame: Baseline, Week 10 through Week 12

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • UConn Health

    Farmington, Connecticut

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital

    Atlanta, Georgia

  • Henry Ford Health System

    Detroit, Michigan

  • Children's Hospital of Michigan

    Detroit, Michigan

  • Icahn School of Medicine at Mt. Sinai

    New York, New York

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Prisma Health Cancer Institute - Farris Road

    Greenville, South Carolina

  • University of Texas Health Science Center of Houston

    Houston, Texas

  • Fred Hutchinson Cancer Center, University of Washington

    Seattle, Washington

  • CHR de la Citadelle

    Liège, Wallonne, Belgium

  • CHU Montreal

    Montreal, Quebec, Canada

  • Hôpital Edouard Herriot, CHU de Lyon

    Lyon, Auvergne-Rhône-Alpes, France

  • CHU Hôpital Henri Mondor

    Créteil, Île-de-France Region, France

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, Midi Pyrenees, France

  • St. James Hospital

    Dublin, Leinster, Ireland

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Amsterdam Universitair Medisch Centrum, Locatie AMC

    Amsterdam, North Holland, Netherlands

  • Erasmus MC

    Rotterdam, South Holland, Netherlands

  • University College London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.